Walleye Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Walleye Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-71,149	Closed	-$1.76M	–	4794
2026 Q1	$1.76M	Buy	71,149 +51,010	+253%	+$1.22M	0.01%	1574
2025 Q4	$470K	Buy	+20,139	New	+$449K	﹤0.01%	2998
2025 Q1	–	Sell	-14,183	Closed	-$296K	–	4373
2024 Q4	$296K	Sell	14,183 -234,105	-94%	-$5.03M	﹤0.01%	3437
2024 Q3	$4.94M	Buy	+248,288	New	+$4.6M	0.01%	1180
2024 Q2	–	Sell	-21,302	Closed	-$340K	–	5649
2024 Q1	$340K	Buy	+21,302	New	+$321K	﹤0.01%	3541
2023 Q4	–	Sell	-20,549	Closed	-$240K	–	5016
2023 Q3	$240K	Buy	20,549 +8,650	+73%	+$116K	﹤0.01%	3409
2023 Q2	$160K	Buy	+11,899	New	+$171K	﹤0.01%	3215
2020 Q2	–	Sell	-12,000	Closed	-$46K	–	664
2020 Q1	$46K	Buy	+12,000	New	+$49.3K	0.01%	696

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Capital's CPRX Position: Q2 2026 in Review

Walleye Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 71,149 shares — an estimated $1.76M sold.

Walleye Capital first reported a position in CPRX in Q1 2020 and held it in 8 quarters. The position peaked at $4.94M in Q3 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Walleye Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 71,149 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.76M.
Walleye Capital first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 8 quarters.
Walleye Capital's Catalyst Pharmaceutical position peaked at $4.94M in Q3 2024.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.